Related Experiment Video
Updated: Jan 8, 2026

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
Published on: July 21, 2017
One small molecule for man, one giant leap for mankind with obesity
Aaron Novikoff1, Timo D Müller2
1Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Munich, Munich, Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
None:
The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinical trial, delivers meaningful reductions in body weight and improvements in metabolic health. This advancement moves beyond peptide-based injectables, paving the way for potent obesity therapies that are simpler, more affordable, and accessible to millions worldwide.
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Obesity
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Regulation of Food Intake
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

